Anticodon Engineered Transfer RNA (tRNA^SUAG) Inhibits Hepatitis B Virus Replication by Promoting the Degradation of Core Protein.

ABSTRACT: Current antiviral drugs targeting the hepatitis B virus (HBV) still face challenges in achieving a functional cure for chronic hepatitis B. Therefore, it is necessary to explore new therapeutic approaches and combined therapy strategies. Anticodon engineered transfer RNA (ACE-tRNA) has been widely applied in the treatment of genetic diseases caused by nonsense mutations. However, its role in antiviral therapy has not been reported yet. In this study, ACE-tRNAs are designed to target the highly conserved stop codon (UAG) of HBV core protein (HBc). All designed ACE-tRNAs can read through the stop codon of HBc. Among them, tRNA^SUAG might promote HBc phosphorylation by introducing a phosphorylatable serine into the C-terminal domain of HBc, thereby potentially reducing HBc levels an

SUBMITTER: Yang X 

PROVIDER: S-EPMC12677619 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature